Latest research on Sevelamer

Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. When taken with meals, sevelamer binds to dietary phosphate and prevents its absorption. It is marketed by Genzyme under the trade name Renagel.

Latest findings

The authors comment that these results show that Sevelamer is highly cost-effective, as the median cost-effectiveness of dialysis is $US46 000 per life-year gained (Caro et al. 2003). [source, 2005]
However, there has been debate over the cost-effectiveness of Sevelamer (Quinibi & Nolan 2005), and direct evidence of the economic effects of Sevelamer is required to confirm these estimates. [source, 2005]
A case–control study reported that average total Medicare expenditure during the 17-month study was lower in patients receiving Sevelamer than in matched controls not receiving Sevelamer ($US4422 vs $US5866 per patient per month) (Collins et al. 2000). [source, 2005]
A decision-analysis model estimated the costs and cost-effectiveness of Sevelamer compared with Calcium carbonate plus Atorvastatin for reducing LDL cholesterol in patients with CKD (Brophy et al. 2000). [source, 2005]
However, the Sevelamer data used to populate the model were derived from seven published Sevelamer trials, six of which were conducted in hemodialysis patients (the other was in healthy volunteers), so the study is relevant to a review of Sevelamer in hemodialysis patients. [source, 2005]
The study estimated that the total annual cost of treatment with Calcium carbonate (1 g three times per day) plus Atorvastatin (10 mg/day) was $US1029 per patient, while the cost of treatment with Sevelamer (2 × 403 mg capsules three times per day) was $US1579 per patient. [source, 2005]
At the end of this period, the patients will be stratified according to residual renal function (greater or less than 100 ml urine output/day/1.73 m2) and the type of phosphate binder therapy (Sevelamer vs. calcium-containing phosphate binders), since these variables may affect the overall efficacy of metabolic acidosis control. [source, 2004]